Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the 3SBio’s SSGJ-707.

Industry Veteran and Former Pfizer Chief Scientific Officer Brings Extensive R&D and Leadership Experience to Advance BenchSci's Mission of Improving the Speed and Quality of Preclinical R&D ...

The antibody discovery market is expanding, driven by the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular and ...

MSD has joined fellow big pharmas in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027.

HBCU Fellow Tre’von Conner shares how the IKNS curriculum at Columbia is helping him learn how to effectively tackle ...

The International Chamber of Commerce (ICC), the world business organization representing more than 4.5-million-member ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Modernisation without equity risks deepening health inequalities The NHS 10 year plan promises radical and aspirational transformations in healthcare delivery, but it risks recreating and perpetuating ...